BiomarkersHumans
Real‐World Experience With Plasma PTAU217 as a Screening Tool of Patients at Risk of Alzheimer's Disease in a Memory Clinic
AAIC 2025 Abstract
Abstract
Background: With the approval of Disease Modifying Drugs for Alzheimer's disease (AD), emerging clinical trials and unknowns in etiology, the clinical use of plasma biomarkers is increasingly becoming a reality.
The paper
María Capdevila, Raquel Puerta, Laura Montrreal, Amanda Cano
Show 14 more authors
Álvaro Muñoz-Morales, Clàudia Olivé, Itziar de Rojas, Pablo García‐González, Marta Martinez, Adelina Orellana, Natalia Tatinya, Montserrat Alegret, Pilar Sánz, Victoria M. Fernandez, Sergi Valero, Marta Marquié, Mercè Boada, Agustı́n Ruiz,Fundació ACE
AAIC 2025 Abstract · 24 Dec 2025 · CC BY
Presented at AAIC 2025
